Skip to main content

TD 360 Videos

Abnormal Involuntary Movement Scale (AIMS) Exam

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.
From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.

Diagnosis Discussion Points

Drs. Jain and Kumar explain the importance of properly screening for tardive dyskinesia in patients on antipsychotics.
Drs. Jain and Kumar talk about understanding and differentiating between tardive dyskinesia phenotypes.
Drs. Jain and Kumar discuss implications of functional impairment associated with tardive dyskinesia.
Drs. Jain and Kumar discuss the differences between dyskinesia, akathisia, dystonia, and more.
Drs. Jain and Kumar discuss the differences between tardive dyskinesia and drug-induced parkinsonism.

Treatment Discussion Points

Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Drs. Jain and Kumar discuss what clinicians should expect when prescribing a VMAT2 inhibitor.
Drs. Jain and Kumar review dosing and duration of VMAT2. More Videos
Drs. Jain and Kumar explain QTc warnings as they relate to VMAT2 inhibitors for the treatment of tardive dyskinesia.
Drs. Jain and Kumar review side-effects of deutetrabenazine and valbenazine. More Videos
Drs. Jain and Kumar review practical tips to increase adherence to tardive dyskinesia treatment.
Drs. Jain and Kumar provide practical tips to overcome obstacles in VMAT2 inhibitor prescription approval.
Drs. Jain and Kumar discuss anticholinergics as they relate to the treatment of tardive dyskinesia.
Drs. Jain and Kumar review alternative treatments to treat tardive dyskinesia. More Videos

Miscellaneous

Dr. Rakesh Jain (a psychiatrist) and Dr. Rajeev Kumar (a neurologist) discuss the importance of collaboration between psychiatry and neurology, particularly as it relates to tardive dyskinesia diagnosis and treatment.
Listen to a variety of patients talk about how tardive dyskinesia has impacted their daily life.
Drs. Jain and Kumar interview Karen, a psychotherapist who retired from practice in December 2017 after struggling to cope with her tardive dyskinesia and akathisia.
See first-hand the impact VMAT2 inhibitors have on improving patient symptoms and quality of life after just 24 hours on medication.
Joseph P. McEvoy, MD, discusses new strategies for treating tardive dyskinesia. Dr. McEvoy is Professor of Psychiatry and Health Behavior and the I. Clark Case Chair in Psychotic Disorders at the Medical College of Georgia.
Back to Top